BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21711221)

  • 1. 89Zr radiochemistry for positron emission tomography.
    Severin GW; Engle JW; Barnhart TE; Nickles RJ
    Med Chem; 2011 Sep; 7(5):389-94. PubMed ID: 21711221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review on production of 89Zr in a medical cyclotron for PET radiopharmaceuticals.
    Kasbollah A; Eu P; Cowell S; Deb P
    J Nucl Med Technol; 2013 Mar; 41(1):35-41. PubMed ID: 23327781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
    Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.
    Vosjan MJ; Perk LR; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
    Nat Protoc; 2010 Apr; 5(4):739-43. PubMed ID: 20360768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of clinical-grade (89) Zr-panitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor-targeted therapy.
    Wei L; Shi J; Afari G; Bhattacharyya S
    J Labelled Comp Radiopharm; 2014 Jan; 57(1):25-35. PubMed ID: 24448743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 89Zr-PET radiochemistry in the development and application of therapeutic monoclonal antibodies and other biologicals.
    Vugts DJ; Visser GW; van Dongen GA
    Curr Top Med Chem; 2013; 13(4):446-57. PubMed ID: 23432007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.
    Salih AK; Raheem SJ; Garcia MD; Ahiahonu WK; Price EW
    Inorg Chem; 2022 Dec; 61(51):20964-20976. PubMed ID: 36516446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing the magic bullet? The advancement of immuno-PET into clinical use.
    Wright BD; Lapi SE
    J Nucl Med; 2013 Aug; 54(8):1171-4. PubMed ID: 23908265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.
    Deri MA; Zeglis BM; Francesconi LC; Lewis JS
    Nucl Med Biol; 2013 Jan; 40(1):3-14. PubMed ID: 22998840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects.
    Pandey MK; DeGrado TR
    Curr Radiopharm; 2021; 14(4):325-339. PubMed ID: 32867656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET tracers based on Zirconium-89.
    Zhang Y; Hong H; Cai W
    Curr Radiopharm; 2011 Apr; 4(2):131-9. PubMed ID: 22191652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully Automated
    Poot AJ; Adamzek KWA; Windhorst AD; Vosjan MJWD; Kropf S; Wester HJ; van Dongen GAMS; Vugts DJ
    J Nucl Med; 2019 May; 60(5):691-695. PubMed ID: 30530830
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Heskamp S; Raavé R; Boerman O; Rijpkema M; Goncalves V; Denat F
    Bioconjug Chem; 2017 Sep; 28(9):2211-2223. PubMed ID: 28767228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized methods for the production of high specific-activity zirconium-89.
    Holland JP; Sheh Y; Lewis JS
    Nucl Med Biol; 2009 Oct; 36(7):729-39. PubMed ID: 19720285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Perspectives on
    Yoon JK; Park BN; Ryu EK; An YS; Lee SJ
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560337
    [No Abstract]   [Full Text] [Related]  

  • 19. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.